A medication that can support weight loss, lower diabetes risk, and protect your heart sounds almost too good to be true. So we get practical about the real decision: not “Do I want a GLP-1?” but “What problem am I trying to solve?” If the goal is better metabolic health, less sleep apnea burden, improved blood pressure, or a long-term plan for obesity as a chronic disease, the conversation changes fast.

We break down who should seriously consider GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro, including the common BMI thresholds and the “BMI plus comorbidity” situations. We also talk about the people who have truly done the nutrition and exercise work, lost weight, and watched their body push back with hunger and regain. That’s where appetite dysregulation and biology matter, and where GLP-1s can become a powerful tool instead of a moral debate.

We also cover who should pause before starting: anyone chasing a quick fix, anyone who hasn’t built foundational habits, or anyone who isn’t ready for the trade-offs like nausea, fatigue, or constipation. We dig into safety and long-term expectations, why stopping often brings symptoms back, and why easy access through med spas and low-oversight online clinics can be risky, especially with disordered eating history. If you want a calmer, more responsible way to decide, we’ll help you map the choice to your story.

Subscribe for more practical health conversations, share this with a friend who’s on the fence, and leave a review if it helped. What’s the biggest question you still have about starting a GLP-1?

Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

Support the show

Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

Artwork Rebrand and Avatars:

Vantage Design Works (Vanessa Jones)

Website: https://www.vantagedesignworks.com/

Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr

Original Artwork Concept: Olivia Pawlowski